Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medicare Policy Pricing Debate

CVS Medicare Part D Plan With Pass-Through Rebates Has Limited Uptake

  • News

Executive Summary

Low enrollment indicates that beneficiaries have trouble figuring out whether reductions in cost sharing would offset a much higher premium.

You may also be interested in...



Part D Rebates: Policy Tweak Would Retain Manufacturer ‘Contributions’

Peter Bach’s new approach to calculating TrOOP cost in Medicare would prevent big savings to manufacturers from point-of-sale rebates.

CVS Offering Point-Of-Sale Rebates In Part D Next Year With SilverScript Plan

Premiums will average about $80 for enhanced plan, well above average $32.50 premium for basic stand-alone Medicare Part D coverage in 2019.

Point-Of-Sale Rebates In Part D Could Save Seniors $20bn, PhRMA Argues

PhRMA President Ubl discusses drug pricing advocacy priorities in Medicare Part D during media briefing.

Table

View full table

Topics

Related Companies

Tags:
Medicare Policy Pricing Debate
Latest Headlines

Pink Sheet Podcast: CAR-T Malignancy Reports, Background Music In DTC Ads, New No. 2 At US FDA

‘Vast Amount Of Valuable Input’ Leads Australia To Extend HTA Review

French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine

US FDA’s Patient-Focused Drug Development Program Meetings Evolve With Technology Focus

See All
UsernamePublicRestriction

Register

PS124575

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By